Prothena Corporation plc (NASDAQ:PRTA) Q4 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Prothena Biosciences Fourth Quarter and Full Year 2025 Financial Results Conference Call.
Prothena Corp Public Ltd Co (PRTA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Persistent Asset Partners Xin Huang | 38,100 | $372,999 | 0.11% | |
| 2. | Winton Capital Management David Harding | 30,500 | $298,595 | -13% | 0.01% |
| 3. | NVerses Capital Jb Kim | 13,246 | $129,678 | 0.2% | |
| 4. | Walleye Capital Will England | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.62 | 3,500 | $30,167.20 | 83,500 | 2026-08-07 | Filing | |
| $8.62 | 34,000 | $293,052.80 | 790,000 | 2026-08-07 | Filing | |
| $7.90 | 20,000 | $157,990.00 | 756,000 | 2026-06-16 | Filing | |
| $8.17 | 125,000 | $1,021,225.00 | 1,061,000 | 2026-06-11 | Filing | |
| $9.31 | 50,000 | $465,295.00 | 936,000 | 2026-06-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.47 | 7,662 | $64,919.36 | 55,782 | 2026-07-29 | Filing | |
| $8.47 | 8,386 | $71,055.42 | 35,745 | 2026-07-29 | Filing | |
| $7.64 | 1,984,053 | $15,164,712.29 | 5,304,596 | 2025-05-06 | Filing | |
| $8.11 | 977,693 | $7,930,165.69 | 7,288,649 | 2025-05-05 | Filing | |
| $8.36 | 3,317,938 | $27,744,929.35 | 8,266,342 | 2025-05-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,867,955 | $47,657,280 | 0% | |
| 2. | 2,393,424 | $23,431,621 | 0% | |
| 3. | 1,125,877 | $11,024,980 | 0% | |
| 4. | 1,084,401 | $10,616,286 | 0.02% | |
| 5. | 905,651 | $8,867,349 | 0% |
News See All
Prothena Corporation plc (PRTA): A Bull Case Theory
This stock is one of several featured in our latest research.
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation
The price target decrease followed the company's May 23 announcement stating that its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients failed to meet the primary endpoint, resulting...
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure
Although the firm is bullish on Prothena Corporation plc (NASDAQ:PRTA), it reduced its price target after the company announced the discontinuation of its Phase 3 AFFIRM-AL clinical trial for Birtamimab...
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT
The price target decrease followed the company's announcement on May 23 that its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients had failed to meet the primary endpoint.
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails
The notable price target decrease came after Prothena Corporation plc (NASDAQ:PRTA) announced negative results from the Phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis on May 23.
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform
This rating update came after Prothena Corporation's (NASDAQ:PRTA) May 23 announcement that its Phase 3 AFFIRM-AL trial for birtamimab in amyloid light chain amyloidosis failed to meet the primary endpoint...
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results
The considerable price target reduction followed the company's announcement regarding the discontinuation of its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients, as it could...
Hedge Fund Resource Center